Human MOG ELISA Kit (V2LY-0626-LY3614)

Go to compare Compare Online Inquiry
Tested Data
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Sensitivity
4.84 ng/mL
Detection Range
10-2000 ng/mL
Sample Type
Serum, Plasma, cell culture supernates
Specificity
Human
Assay Type
Sandwich
Reactivity
Human
Assay Time
1.5 h
Molecule Mass
28.2 kDa
Components
  • Pre-coated ELISA Plate: 12 wells * 8 detachable strips
  • Standard solution: 0.5ml x1
  • Standard diluent: 3ml x1
  • Streptavidin-HRP: 6ml x1
  • Stop solution: 6ml x1
  • Substrate solution A: 6ml x1
  • Substrate solution B: 6ml x1
  • Wash buffer concentrate (25x): 20ml x1
  • Biotinylated antibody: 1ml x1

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 2-8°C
More Infomation

Target

Full Name
Myelin Oligodendrocyte Glycoprotein
Function
Mediates homophilic cell-cell adhesion (By similarity).

Minor component of the myelin sheath. May be involved in completion and/or maintenance of the myelin sheath and in cell-cell communication.

(Microbial infection) Acts as a receptor for rubella virus.
Biological Process
Cell adhesion Source: UniProtKB-KW
Central nervous system development Source: ProtInc
Regulation of cytokine production Source: GO_Central
T cell receptor signaling pathway Source: GO_Central
Cellular Location
Cell membrane
Involvement in disease
Narcolepsy 7 (NRCLP7):
Neurological disabling sleep disorder, characterized by excessive daytime sleepiness, sleep fragmentation, symptoms of abnormal rapid-eye-movement (REM) sleep, cataplexy, hypnagogic hallucinations, and sleep paralysis. Cataplexy is a sudden loss of muscle tone triggered by emotions, which is the most valuable clinical feature used to diagnose narcolepsy. Human narcolepsy is primarily a sporadically occurring disorder but familial clustering has been observed.
Topology
Extracellular: 30-154
Helical: 155-175
Cytoplasmic: 176-210
Helical: 211-231
Extracellular: 232-247

Carta, S., Cobo Calvo, Á., Armangué, T., Saiz, A., Lechner, C., Rostásy, K., ... & Mariotto, S. (2023). Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study. Neurology, 100(11), e1095-e1108.

Corbali, O., & Chitnis, T. (2023). Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Frontiers in Neurology, 14, 1137998.

Kwon, Y. N., Kim, B., Kim, J. S., Mo, H., Choi, K., Oh, S. I., ... & Kim, S. M. (2021). Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurology: Neuroimmunology & Neuroinflammation, 9(1), e1095.

Marignier, R., Hacohen, Y., Cobo-Calvo, A., Pröbstel, A. K., Aktas, O., Alexopoulos, H., ... & Hemmer, B. (2021). Myelin-oligodendrocyte glycoprotein antibody-associated disease. The Lancet Neurology, 20(9), 762-772.

Sechi, E., Buciuc, M., Pittock, S. J., Chen, J. J., Fryer, J. P., Jenkins, S. M., ... & Flanagan, E. P. (2021). Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA neurology, 78(6), 741-746.

Foiadelli, T., Gastaldi, M., Scaranzin, S., Franciotta, D., & Savasta, S. (2020). Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: two paradigmatic cases and a review of the literature. Multiple Sclerosis and Related Disorders, 41, 102011.

Takai, Y., Misu, T., Kaneko, K., Chihara, N., Narikawa, K., Tsuchida, S., ... & Japan MOG-antibody Disease Consortium Otsuka Yoshihisa Nishimaki Keiichi Ishigaki Sho Yoshida Kazunari Iguchi Yasuyuki Fukuda Takahiro Nohara Seitaro Tamaoka Akira Fujimori Juichi. (2020). Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain, 143(5), 1431-1446.

Ambrosius, W., Michalak, S., Kozubski, W., & Kalinowska, A. (2020). Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. International journal of molecular sciences, 22(1), 100.

Reindl, M., & Waters, P. (2019). Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nature Reviews Neurology, 15(2), 89-102.

Tea, F., Lopez, J. A., Ramanathan, S., Merheb, V., Lee, F. X., Zou, A., ... & Brilot, F. (2019). Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathologica Communications, 7, 1-22.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Human MOG ELISA Kit?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.